Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not recruiting

Study on Colchicine for Reducing Inflammation in Patients with Type 1 Diabetes

Verified siteRegistered drug
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying the effects of a medication called colchicine in people with Type 1 diabetes. Type 1 diabetes is a condition where the body does not produce insulin, a hormone needed to control blood sugar levels. The trial aims to see if colchicine can help reduce inflammation in the body, which is often a concern for people with this type of diabetes. Participants in the study will either receive colchicine or a placebo, which looks like the medication but does not contain the active ingredient.

The purpose of the study is to determine how colchicine affects levels of a protein in the blood called high-sensitivity C-reactive protein, which is a marker of inflammation. The study will last for 26 weeks, during which participants will take the medication or placebo orally in the form of tablets. Throughout the study, various health indicators will be monitored, including blood sugar levels, insulin usage, body weight, and cholesterol levels, to understand the broader effects of colchicine on health.

By the end of the study, researchers hope to gather valuable information on whether colchicine can be an effective treatment for reducing inflammation in people with Type 1 diabetes. This could potentially lead to new ways of managing the condition and improving the quality of life for those affected. The study is designed to be thorough and will carefully monitor participants' health to ensure safety and gather accurate results.

The research process

The trial runs in 5 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Initial visit

    Upon joining the study, you will attend an initial visit. During this visit, your eligibility will be confirmed based on specific criteria such as having type 1 diabetes for more than five years, being between 18 and 80 years old, and having stable insulin therapy.

    Your medical history will be reviewed, and baseline measurements will be taken, including blood tests to measure C-reactive protein levels and other health indicators.

  2. Step 2

    Randomization

    After the initial visit, you will be randomly assigned to one of two groups. One group will receive the medication colchicine, and the other group will receive a placebo (a tablet that looks like the medication but has no active ingredients).

    This process is double-blind, meaning neither you nor the study team will know which group you are in.

  3. Step 3

    Medication administration

    You will take the assigned tablet orally once a day for a duration of 26 weeks. It is important to take the tablet at the same time each day to maintain consistency.

    You will be provided with instructions on how to take the medication and what to do if you miss a dose.

  4. Step 4

    Follow-up visits

    Throughout the 26-week period, you will have regular follow-up visits. These visits will include health assessments and blood tests to monitor your C-reactive protein levels and other health markers.

    You will also be asked about any side effects or changes in your health.

  5. Step 5

    Final assessment

    At the end of the 26 weeks, you will have a final assessment. This will include a comprehensive review of your health, including blood tests and other measurements.

    The study team will discuss the results with you and provide any necessary follow-up care or instructions.

Who can join the trial?

7 criteria

  • Have been diagnosed with Type 1 diabetes for more than five years.
  • Be between the ages of 18 and 80 years old.
  • Have an HbA1c level of less than 80 mmol/mol. HbA1c is a measure of your average blood sugar levels over the past 2 to 3 months.
  • Be on stable insulin therapy, meaning no recent changes in insulin brand or starting new insulin delivery methods like pumps or multiple daily injections, for at least 3 months. If using glucose monitoring technology, it should also be stable for at least 3 months.
  • Have a C-reactive protein level of 2 mg/l or higher. This is a blood test that measures inflammation in the body.
  • Have an estimated glomerular filtration rate greater than 50 ml/min/1.73 m². This is a test to check how well your kidneys are working.
  • Have either stable atherosclerotic cardiovascular disease or be at high risk for it. This includes conditions like heart disease, previous heart attacks, strokes, or other related conditions. High risk is defined by specific medical guidelines or a 10-year cardiovascular risk of 20% or more.

Who cannot join the trial?

1 criterion

  • Patients with **Type 1 diabetes** cannot participate.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

Colchicine is a medication that is being studied for its potential to reduce inflammation in people with type 1 diabetes. In this trial, researchers are looking at how colchicine affects the levels of a specific protein in the blood called high-sensitivity C-reactive protein (hs-CRP). This protein is a marker of inflammation, and by lowering its levels, colchicine might help reduce the risk of complications related to inflammation in diabetes. The study aims to see if colchicine can effectively lower these protein levels over a period of 26 weeks.

What is already known about the treatment

Colchicine – Colchicine is administered orally in the form of tablets. It is currently being studied in clinical trials for its potential to reduce inflammation in people with type 1 diabetes. The main therapeutic indication being explored is its ability to lower levels of high-sensitivity C-reactive protein, a marker of inflammation. At the molecular level, colchicine works by disrupting the formation of microtubules, which are structures within cells that play a role in inflammation. It is classified pharmacologically as an anti-inflammatory agent.

Investigated diseases

Type 1 diabetes – Type 1 diabetes is a chronic condition where the pancreas produces little or no insulin, a hormone needed to allow sugar (glucose) to enter cells to produce energy. The disease typically begins in childhood or young adulthood, but it can develop at any age. It progresses as the immune system mistakenly attacks and destroys insulin-producing beta cells in the pancreas. As a result, blood sugar levels become elevated, leading to symptoms such as increased thirst, frequent urination, hunger, fatigue, and blurred vision. Over time, if not managed, it can lead to complications affecting the heart, blood vessels, nerves, eyes, and kidneys. The progression of the disease requires ongoing monitoring and management of blood sugar levels.
Trial detailsLast updated 7 Oct 2026
Age18+ yearsPhasePhase IITrial ID2022-502038-23-00Protocol codeThe REC1TE trialSponsorGentofte Hospital

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.